| Literature DB >> 28590454 |
Maria Pilar Vinardell1, Montserrat Mitjans2.
Abstract
A review of the pharmacological applications of lignins provides evidence of their protective role against the development of different diseases. In many cases, the effects of lignins could be explained by their antioxidant capacity. Here, we present a systematic review of the literature from the period 2010-2016 which provides information concerning new applications of lignins derived from recent research. The most promising findings are reported, including the methodologies employed and results obtained with lignins or their derivatives which may improve human health. We highlight potential applications in the treatment of obesity, diabetes, thrombosis, viral infections and cancer. Moreover, we report both that lignins can be used in the preparation of nanoparticles to deliver different drugs and also their use in photoprotection.Entities:
Keywords: antioxidant capacity; antiviral effect; applicability; human health; lignin
Mesh:
Substances:
Year: 2017 PMID: 28590454 PMCID: PMC5486042 DOI: 10.3390/ijms18061219
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Schematic representation of a softwood lignin structure showing the different linkages. (Reprinted with permission from [5]).
Figure 2Effect of lignosulfonic acid on preadipocyte proliferation. (a) Lignosulfonic acid was added to 3T3-L1 preadipocyte cells at concentrations of 1.0 mg/mL and 2.0 mg/mL compared to control in the absence of lignosulfonic acid; (b) effect of lignosulfonic acid on the expression of C/EBP-β; (c) LDH content released into culture medium. Statistical significance was evaluated by Student’s t-test (* p < 0.05). (Reprinted with permission from [16]).
Figure 3Effect of Lignophenols (LPs) on the amount of cellular total cholesterol in HepG2 cells incubated for 48 h in serum-free media containing different concentrations of LPS. The differences between means were significant at ** p < 0.01, compared with oleate-treated cultures (Reprinted with permission from [20]).
Figure 4Cytotoxicity of Lignosulfonic acid (LA) on human T-cell leukemia cell line (MT-4) cells, human embryonic kidney cells (HEK293T) and peripheral blood mononuclear cells (PBMCs). (A) Dose dependent anti-HIV activity of LA in the CD4+ T-lymphoma cell line MT-4 against 3 laboratory HIV-1 strains (NL4.3, IIIB and HE) and 1 HIV-2 strain (ROD); (B) Evaluation of the IC50s of LA against various clinical isolates representing different of HIV-1 primary cells; (C) Dose-dependent effect of LA on the giant cell (syncytia) formation between persistently HIV-1 IIIB-infected T cells (HUT-78/IIIB) and non-infected CD4+ target SupT1 T cells; (D) Dashed lines correspond to 50%, (Reprinted with permission from [25]).
Figure 5Sulfated low molecular weight lignins are complex three-dimensional oligomers obtained from enzymatic condensation of 4-hydroxycinnamic acid monomers using horseradish peroxidase followed by chemical sulfation using sulfur trioxide. The oligomers primarily contain β-O-4, β-5 and β–β inter-residue linkages (shown shaded). (Reprinted with permission from [43]).
Figure 6Schematic representation of the three types of lignin nanoparticles (LNPs) (A), and TEM images of (B) pLNPs, (C) Fe-LNPs and (D) Fe3O4-LNPs and magnification of the Fe3O4 NPs inside the LNPs. (Reprinted with permission from [52]).
Figure 7Scanning electron microcopy (SEM) images of (a) Zinc oxide nanoparticles (b) ligninnanoparticles organosolv and (c) lignin nanoparticles soda. (Reprinted with permission from [53].
Main pharmacological activities of lignins and their derivatives.
| Compound | Effect | Mechanism | Experimental Model | Reference |
|---|---|---|---|---|
| Alkali lignin | Antidiabetic | α-amylase inhibition In vitro decreased glucose diffusion | In vitro glucose movement | [ |
| Lignosulfonic acid | Antidiabetic | Inhibitor of α-glucosidase Decrease blood glycemia | In vitro inhibitor of α-glucosidase Rat in vivo | [ |
| Lignophenols | Obesity control | Decrease oleate-induced apo-B secretion | HepG2 in vitro | [ |
| Lignophenols | Obesity control | Decrease plasma triglyceride levels | Rats fed a high-fat diet | [ |
| Lignosulfonic acid | Antiviral activity | Inhibition of the replication of herpes simplex virus (HSV) | Infected mice by exposing scarified skin to an HSV-2 G | [ |
| Lignosulfonic acid (LA) | Antiviral activity | LA mainly binds to the HIV-1 envelope glycoproteins | In vitro cells: T-lymphoma cell lines, HEK293T, HUT-78, Monocyte-derived dendritic cells | [ |
| Lignin–carbohydrate complexes | Antiviral activity | Inhibiting viral binding and penetration | Vero cells infected with herpes simplex virus | [ |
| Lignin–carbohydrate complexes | Antiviral activity | Inhibiting viral binding and penetration | HeLa cells infected with herpes simplex virus | [ |
| Sulfated low-molecular-weight lignins | Anticoagulant | Inhibition of thrombin | Binding to thrombin | [ |
| Sulfated low-molecular-weight lignins | Anticoagulant | Allosteric inhibition of thrombin | Whole blood thromboelastography, hemostasis analysis and mouse arterial thrombosis models | [ |
| Sulfated low-molecular-weight lignins | Antiemphysema | Elastase, oxidation and inflammation inhibition | In vitro human alveolar A549 and bronchial Calu-3 epithelial cells | [ |